Hepatoma after thorotrast. Morphological and autoradiographic data

Area of Science:

• Hepatology
• Radiology
• Oncology

Background:

• Thorotrast, a radioactive colloidal suspension, was used as a contrast agent for diagnostic imaging.
• Long-term retention of Thorotrast in the liver and spleen poses potential health risks due to its radioactivity.
• Hepatoma, a primary liver cancer, can arise from chronic liver damage and exposure to carcinogens.

Purpose of the Study:

• To investigate the long-term effects of Thorotrast exposure.
• To analyze the role of Thorotrast in the development of hepatoma.
• To understand the mechanisms of Thorotrast-induced tumor formation.

Main Methods:

• Morphological examination of liver and spleen tissues.
• Macro-autoradiography to assess radioactivity distribution.
• Micro-autoradiography to determine cellular-level radiation exposure.

Main Results:

• Hepatoma was diagnosed in two women with a history of Thorotrast administration 30 and 40 years prior.
• Thorotrast accumulation was confirmed in the liver and spleen tissues studied.
• The study discussed the contribution of Thorotrast to the neoplastic process and tumor induction.

Conclusions:

• Thorotrast exposure can lead to hepatoma development decades after administration.
• The study highlights the carcinogenic potential of Thorotrast.
• Understanding Thorotrast's role in tumorigenesis is crucial for managing long-term health risks.